Lyell Immunopharma annual meeting elects Class I directors, ratifies auditor

Lyell Immunopharma, Inc.

Elected Hans Bishop, Catherine Friedman, Robert Nelsen as Class I directors; each received >147M votes for.
Ratified Ernst & Young LLP as independent auditor for FY2022; 192.2M for, 1,241 against.
Quorum achieved with 192,242,640 shares (77.79%) present at June 8, 2022 annual meeting.

item 5.07

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-172997

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.